Regenerative Medicine Minnesota aims to improve the health of Minnesotans by advancing regenerative medicine research, education, industry and care delivery to patients. This state-wide initiative will furthermore open new economic opportunities through commercialization of technologies. Regenerative Medicine Minnesota leverages the strengths of Minnesota institutions to position the state at the forefront of regenerative medicine.
In May of 2014, the Minnesota State Legislature allocated $4.5 million (the first year) and $4.35 million of support per year thereafter, to fund research, education, patient care, and business development initiatives that improve or increase access to regenerative medicine throughout the state. Read the bill.
Improving the health of Minnesotans by advancing regenerative medicine therapies.
Advance regenerative medicine research, education, industries, and care delivery to patients.
Establish Minnesota at the forefront of regenerative medicine science and practice.
Scientific – Support Minnesota research that has the potential to translate into clinical advances in regenerative medicine.
Commercial – Develop Minnesota businesses and infrastructure to deliver regenerative medicine products and services.
Educational – Educate, recruit and retain a regenerative medicine workforce in Minnesota.
– Educate Minnesotans about the status and potential of regenerative medicine therapies.
Clinical – Advance regenerative medicine therapies to the clinic.
Recommendations governing the Regenerative Medicine Minnesota (RMM) funding will be made by a five-person Board. The Regenerative Medicine Minnesota Board (Board) will have representatives from the University of Minnesota and Mayo Clinic as co-chairs, with three additional Minnesotans from fields as diverse as patient advocacy, industry, and health care. Members will also preferably have expertise pertinent to regenerative medicine, medical or basic science research, clinical translation, and/or business development.
The Board is responsible for approving a business plan (new version 8-20-2019) that outlines the RMM’s vision, goals, objectives, funding priorities, and marketing and communications efforts. The board is also responsible for overseeing the review of applications and providing recommendations for distribution of funds. The Board has the authority to recommend reallocating funding among RMM funding categories based on need or on the quality of applications received. The Board is responsible for overseeing the progress of funded projects and for approving reports to be submitted to the State of Minnesota as mandated in the appropriations bill. Board meeting minutes are available here.
The oversight of RMM lies with senior officials of the University of Minnesota (Vice President for Research and Vice Dean for Research, Medical School) and Mayo Clinic (Executive Dean for Research and the Director of the Center for Clinical and Translational Science). To ensure that RMM meets the legislative intent of a broad statewide program and that the program meets all requisite legal and financial requirements, these four officials will act together to provide final oversight of the business plan and RMM board recommendations regarding funding and other strategic issues. RMM is independent of other University-Mayo collaborations.
Regenerative medicine assists the body’s own ability to heal. Cell and developmental biology, regenerative pharmacology and immunology, medicine and surgery, biotechnology, bioengineering, and other relevant fields, are brought together to develop ways to replace, restore, or regenerate damaged or malfunctioning cells, tissues, and organs to help people return to better health.
Regenerative Medicine Minnesota will engage a network of stakeholders to develop regenerative medicine assets throughout the state. Funding opportunities will be balanced across needs in research, clinical practice, business development, and education, and will emphasize statewide access. Eligible institutions include public and private schools, colleges and universities, hospitals and clinics, health departments, research organizations, and biotechnology development or other companies/organizations that are based in the state of Minnesota. Matching funds or in-kind contributions are strongly encouraged.